Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:51:48.255Z.
Consensus retrieved: 2026-10-06T12:14:06.142Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:51:48.255Z.
Quote observation: 2026-10-06T16:49:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0c00d818a788336e8bc85b69affa9d7057207beb35ad975aac8b5a949e44e0f4
Forward PE Ratio (N/A) = Dated Quote Price ($7.10) / Consensus Forward EPS ($-0.40)
FORWARD PE RATIO
N/A
Gyre Therapeutics, Inc.
Market Cap
$791.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $791.07M | N/A |
| Geron Corporation (GERN)vs › | $795.49M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | N/A |
| Apnimed, Inc. (APMD)vs › | $784.52M | N/A |
| InMode Ltd. (INMD)vs › | $805.78M | 10.82 |
| Ardelyx, Inc. (ARDX)vs › | $805.78M | N/A |
| Sana Biotechnology, Inc. (SANA)vs › | $777.83M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $771.75M | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $815.52M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.10, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.40 | $-0.42 – $-0.38 | 2 | n/m |
| 2027-12-31 | $-0.23 | $-0.25 – $-0.22 | 1 | n/m |
| 2028-12-31 | $1.76 | $1.68 – $1.84 | 1 | 4.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
